Rejuvenation Technologies is at the forefront of developing innovative therapies aimed at reversing cellular aging through the extension of telomeres, which are protective DNA sequences at the ends of chromosomes. Their proprietary technology focuses on safely lengthening telomeres in human cells, addressing the fundamental causes of aging-related diseases such as pulmonary fibrosis, liver disease, and bone marrow failure. By utilizing modified mRNA to temporarily activate telomerase—the enzyme responsible for telomere extension—Rejuvenation Technologies aims to enhance cellular regeneration and vitality while minimizing potential side effects through targeted delivery systems.

The company has made significant strides in its research and development pipeline, with over 40 patents granted and more than $8 million in grant funding awarded since 2023. Their clinical trials are designed to evaluate the safety and efficacy of their telomerase activation therapies in various conditions, including chronic liver disease and hematologic disorders. By focusing on precision science and advanced genomic targeting, Rejuvenation Technologies is committed to transforming medicine and extending the healthy years of life through its groundbreaking approach to age reversal.

United States

Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres. The company is focused on developing mRNA therapies to extend the healthspan by preventing and treating chronic age-related diseases.

Rejuvenation Technologies

Company Details